Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07135128) titled 'A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors' on Aug. 14.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Xiaorong Sun

Condition: Advanced Solid Tumor

Intervention: Drug: 225Ac-FAPI-XT

Recruitment Status: Recruiting

Phase: Phase 1

Date of First Enrollment: October 14, 2024

Target Sample Size: 20

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07135128

Published by HT Digital Content Ser...